Monte Rosa Therapeutics and Novartis have deepened their partnership with a deal valued up to $5.7 billion, including a $120 million upfront payment. The collaboration focuses on developing novel immune-targeted molecular glue drugs using Monte Rosa’s QuEEN platform. Novartis secures exclusive rights to an undisclosed target and options for two additional preclinical candidates. Positive early clinical data for Monte Rosa’s VAV1-targeted degrader markers progress in autoimmune and cancer indications, underscoring the growing role of targeted protein degradation in drug development.